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Background: Cyclooxygenase (COX) is a rate-limiting enzyme in prostaglandins synthesis which exists in two
isoforms, COX-1 and COX-2. Over-expression of COX-2 was considered to increase the proliferation and enhance
the invasiveness of breast cancer cells. It was suggested that genetic variations in COX-2 could influence its
expression. Herein, the present study was aimed to investigate the associations between two mostly studied
functional polymorphisms (-765 G > C and 8473 C > T) in COX-2 and breast cancer risk in Chinese Han women.
Methods: In the hospital-based case-control study, 465 breast cancer patients and 799 cancer-free controls were
genotyped for the COX-2 -765 G > C and 8473 C > T polymorphisms using TaqMan assay. We estimated odds ratios
(ORs) and 95% confidence intervals (95% CIs) using the logistic regression.
Results: Compared with the wild genotype of -765 G > C, we found a statistically significant increased risk of breast
cancer associated with the variant genotypes [GC/CC vs. GG: OR = 1.56, 95% CI = 1.11–2.21]. In the stratified analysis,
the increased risk was more predominant among the subgroups of younger subjects (OR = 1.61, 95% CI = 1.00–2.61).
Furthermore, the variant genotypes were associated with large tumor size (OR = 3.01, 95% CI = 1.47–6.12). No significant
association was observed for the 8473 C > T polymorphism.
Conclusions: Our results suggest that the functional -765 G > C polymorphism in the promoter of COX-2 may influence
the susceptibility and progression of breast cancer in the Chinese Han population.
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Breast cancer is the most common malignancy affecting
women worldwide and its incidence rate is increasing in
both developed and developing countries in recent years
[1]. It is the second cause of cancer related mortality fol-
lowing lung cancer. The etiology of breast cancer has not
been completely identified yet, but is thought to be multi-
factorial, with both environmental and genetic factors [2].
Cyclooxygenase is also known as prostaglandin endo-
peroxide synthetase which plays an important role in the
inflammatory process through converting arachidonic acid* Correspondence: dzj0911@126.com
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unless otherwise stated.to prostaglandins [3]. There are two isoforms of COX,
COX-1 and COX-2. COX-1 is constitutive expressed and
presents in many tissues while the inflammatory enzyme
COX-2 is not detected in most normal tissues. However,
COX-2 can be rapidly induced by a variety of mitogenic
and inflammatory stimuli resulting in elevated levels of
prostaglandins which can affect cell proliferation, apoptosis
and angiogenesis, contributing to tumor occurrence and
progression [4-6]. In breast cancer, several studies have
suggested that moderate to high COX-2 expression is
related to the genesis of mammary tumors and the expres-
sion is associated with parameters of aggressive breast
cancer, including large tumor size, positive axillary lymph
node metastases, and HER2-positive tumor status [7-10].
Targeted inhibition of COX-2 could inhibit the prolifera-
tion of breast cancer cell lines in vitro [11].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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to alter its expression and influence the susceptibility
to various carcinomas [12-14], including breast cancer
[15]. The human COX-2 gene (also known as PTGS2) is
located on chromosome 1q25.2-q25.3 and consists of 10
exons spanning 8.3 kb [16]. More than 15 single nucleo-
tide polymorphisms (SNPs) in COX-2 have been identified,
but the most extensively studied polymorphisms are
the -765 G > C (rs20417) in the promoter and the 8473
C >T (rs5275) in the 3′UTR of COX-2. Previous functional
studies have suggested that the -765 G >C polymorphism
may eliminate a Sp1-binding site but create an E2F binding
site and result in altered COX-2 expression [12,13]. The
8473 T >C polymorphism was shown to be associated with
the alteration of mRNA level of the gene as sequences
within the 3′UTR are important for message stability and
translational efficiency [17]. There are also several studies
that have investigated the association between the two
SNPs and breast cancer risk; however the results from
these studies are inconclusive. To make a more precise
estimation, Yu et al. conducted a mete-analysis on the
associations between several COX-2 polymorphisms and
breast cancer risk and suggested borderline significant
increased risk of breast cancer was detected for rs5277 but
no significant association was observed for the -765 G >C
and 8473 C > T polymorphisms [15]. However, of the
studies included in their meta-analysis, only two studies
were conducted in Chinese population and none of the
two studies investigated the rs5277 polymorphism since
the minor allele frequency of rs5277 is very small in
Chinese population [18,19]. Herein, in the present study,
we investigated the association of the -765 G > C and
8473 C > T polymorphisms and breast cancer risk in a
case-control study in a Chinese population.Materials and methods
Study population
Our study consisted of 465 breast cancer patients which
were consecutively recruited between May 2004 and
September 2010 at the Second Affiliated Hospital of
Xi’an Jiaotong University, China [20]. The Cases were
recruited without the restriction of age. All of the patients
were pathologically confirmed, sporadic breast cancer.
Those patients that received chemotherapy or radio-
therapy before surgery or had other type of cancer were
excluded from the present study. For comparison, 799
cancer-free controls were recruited from subjects who
were seeking health care in the outpatient departments
at the hospital and were frequency-matched to the cases
on age (±5 years). Before recruitment, a standard question-
naire was administered through face-to-face interviews by
trained interviewers to obtain information on demographic
data and related factors.Ethics statement
A consent was obtained from each study subject. The
study protocol conformed to the Declaration of Helsinki
and was approved by the ethics committee of the Second
Affiliated Hospital of Xi’an Jiaotong University.
Genotyping
The whole-genome DNA was isolated and purified from
leucocytes of peripheral blood by proteinase K digestion
and phenol/chloroform extraction, as described previously
[20]. The two polymorphisms (-765 G >C and 8473 C >T)
were genotyped by TaqMan MGB technology (Applied
Biosystems, Foster City, CA, USA) according to the manu-
facturer’s instructions. The sequences of primer and probe
for the two SNPs are available on request. The reaction
mixture of 10 μL contained 20 ng genomic DNA, 3.5 μL
of 2 × TaqMan Genotyping Master Mix, 0.25 μL of the
primers and probes mix and 6.25 μL of double distilled
water. The amplification was performed under the follow-
ing conditions: 50°C for 2 min, 95°C for 10 min followed
by 45 cycles of 95°C for 15 sec, and 60°C for 1 min. Amplifi-
cations were performed in the 384-well ABI 7900HT Real
Time PCR System (Applied Biosystems), following the man-
ufacturer’s instructions. After the completion of the amplifi-
cation, the fluorescence intensity in each well of the plate
was read and analyzed with SDS 2.4 automated software.
Four blank controls were included in each plate to ensure
accuracy of the genotyping. About 10% of the samples were
randomly selected for repeated assays, and the results were
in agreement with the results of the first assays.
Statistical analyses
Differences in the distributions of demographic characteris-
tics, selected variables, and frequencies distribution of
genotypes the two SNPs between the cases and controls
were evaluated using the Student’s t-test (for continuous
variables) or χ2-test (for categorical variables). SNP allele
frequencies in the controls were tested against departure
from the Hardy-Weinberg equilibrium (HWE) using a
goodness-of-fit χ2-test before analysis. The associations
between the genotypes of the COX-2 -765 G >C and 8473
C >T polymorphisms and risk of breast cancer and patients’
clinical characteristics were estimated by computing odds
ratios (ORs) and 95% confidence intervals (CIs) from un-
conditional logistic regression analysis with the adjustment
for age and age at menarche. P value less than 0.05 was con-
sidered statistically significant, and all statistical tests were
two sided. All of the statistical analyses were performed with
the software SAS 9.1.3 (SAS Institute, Cary, NC, USA).
Results
Characteristics of the patients and controls
The clinical information of the patients group and the
demographic characteristics of both the cases and controls
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matched on age (P = 0.257). The frequency of individuals
with age at menarche less than 14 was significantly higher
in the case group (case vs. control: 29.3% vs. 22.9%,
P = 0.012). The percent of patients with tumor size less
than 2 cm, 2 to 5 cm and more than 5 cm are 27.1%,
66.7% and 6.2%, respectively.
Association between COX-2 polymorphisms and risk of
breast cancer
The genotype and allele frequencies of the COX-2 -765
G > C and 8473 C > T polymorphisms are shown in
Table 2. The genotype frequencies of the two SNPs in
controls both conformed to HWE (P = 0.203 and 0.117
for -765 G > C and 8473 C > T, respectively). The frequen-
cies of the GG, GC and CC genotype of -765 G >C poly-
morphism among cases were significantly different from
those among controls (P = 0.021). The difference in the
frequencies distribution of G and C allele among caseTable 1 Distributions of select variables in breast cancer
cases and cancer-free controls
Variables Case
(N = 465), %
Control
(N = 799), %
P*
Age at diagnosis or recruitment (year)
Mean ± SD 52.0 ± 11.0 50.8 ± 13.2 0.110
<52 239 51.4 437 54.7 0.257
≥52 226 48.6 362 45.3
Age at menarche (year)
Mean ± SD 14.55 ± 1.84 14.89 ± 1.76 0.002
<14 136 29.3 183 22.9 0.012
≥14 329 70.7 616 77.1
Tumor size
Less than 2 cm 126 27.1
2 to 5 cm 310 66.7













ER, estrogen receptor; PR, progestin receptor; LN, lymph node; HER-2, human
epidermal growth factor receptor 2; *T-test or two-sided χ2-test.and controls were also significant (P = 0.005). Compared
with individuals with COX-2 -765 GG genotype, individual
with GC or GC/CC genotypes both had a significantly
increased susceptibility to breast cancer (OR = 1.55, 95%
CI = 1.09–2.00 and OR = 1.56, 95% CI = 1.11–2.21, respect-
ively). These results suggested that the COX-2 -765 G >C
polymorphism had effect on breast cancer occurrence.
However, we did not observe significant associations
between the COX-2 8473 C > T polymorphism and breast
cancer risk in any comparison, as shown in Table 2.
Stratified analysis of the COX-2 -765 G > C polymorphism
and breast cancer risk
We then evaluated the effect of the COX-2 -765 G > C
polymorphism on breast cancer stratified by age. As shown
in Table 3, the risk effect of the -765 G >C variant geno-
types (GC/CC) were more pronounced in younger subjects
(P = 0.049, OR = 1.61, 95% CI = 1.00–2.61) rather than old
subjects (P = 0.053, OR = 1.60, 95% CI = 0.96–2.68). The
same analyses were also performed for the 8473 C >T
polymorphism, however, no positive result was observed
(data not shown).
Association between the COX-2 polymorphisms and clinical
parameters of breast cancer patients
To determine whether the COX-2 polymorphisms have
effect on the clinical features of breast cancer patients,
we then analyzed the association between the COX-2
polymorphisms and a series of clinicopathologic parame-
ters, including tumor size, lymph node metastasis, and
the statuses of ER, PR and Her-2. As shown in Table 4,
we found the frequency of the variant genotypes of
COX-2 -765 G > C polymorphism was significant higher
in patients with larger tumor size (>2 cm) (P = 0.006,
OR = 3.01, 95% CI = 1.47–6.12).
Discussion
In the present study, we found a significant association
between the COX-2 -765 G >C polymorphism and breast
cancer risk. Compared with individuals with -765GG
genotype, those with GC or GC/CC genotypes had a
significantly increased breast cancer risk of 1.55 and
1.56, respectively. The risk effect was more predomin-
ant in younger individuals. Besides, we also found the
COX-2 -765GC/CC genotypes were associated with lager
tumor size, suggesting the variant genotypes of this poly-
morphism may participate in the progression of breast
cancer.
Over-expression of COX-2 is observed in a variety of
human malignancies and in premalignant lesions [21-23].
It is not only reported to be associated with the develop-
ment of breast cancer but also plays important role in the
progression of the disease. Previous functional studies
suggested that the COX-2 -765 G > C polymorphism
Table 2 Genotype and allele frequencies of the COX-2 polymorphisms among the cases and controls and the
associations with risk the breast cancer
Polymorphisms Case (N = 465) Control (N = 799) P* OR (95% CI)†
N % N %
-765 G > C
GG 394 84.7 719 90.0 0.021 1.00 (reference)
GC 67 14.4 76 9.6 1.55 (1.09–2.20)
CC 4 0.9 4 0.4 1.88 (0.47–7.65)
GG 394 84.7 719 90.0 0.005 1.00 (reference)
GC + CC 71 15.3 80 10.0 1.56 (1.11–2.21)
C 75 8.0 84 5.2 0.005
8473 C > T
TT 299 64.3 515 64.5 0.209 1.00 (reference)
TC 132 28.4 244 30.5 0.93 (0.72–1.21)
CC 34 7.3 40 5.0 1.46 (0.90–2.37)
TT 299 64.3 515 64.5 1.00 (reference)
TC + CC 166 35.7 284 35.5 0.956
C 200 21.5 324 20.3 0.462
CI, confidence interval; OR, odds ratio; Compared with individuals with COX-2 -765 GG genotype, individual with GC or GC/CC genotypes both had a significantly
increased susceptibility to breast cancer. *Two-sided χ2 test for the distributions of genotype and allele frequencies.
†Adjusted for age and age at menarche.
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however, with inconclusive results [12,13]. For instance,
Papafili et al. reported that -765C allele was associated
with significantly reduced COX-2 expression compared
with the -765G allele and they postulated this effect to be
mediated by the loss of Sp1 transcription factor binding to
its cognate element [12]. However, Szczeklik et al. further
demonstrated that -765C had a functional consequence
resulting in enhanced biosynthesis of prostaglandins
through eliminating a Sp1-binding site but creating an
E2F-binding site [13]. Based on these findings, it would be
interesting to investigate whether the COX-2 -765 G > C
polymorphism could be used as a genetic biomarker to
predict cancer susceptibility and progression. In our
study, we have observed that variant genotypes of the
COX-2 -765 G > C (GC/CC) were associated with in-
creased breast cancer risk, and in patients group thatTable 3 Stratification analyses on age between the COX-2 -76
The-765 G > C
genotypes
Case (N = 465)
N % N
Age < 52
GG 204 85.4 395
GC + CC 35 14.6 42
Age≥ 52
GG 190 84.1 324
GC + CC 36 15.9 38
CI, confidence interval; OR, odds ratio. The risk effect of the -765 G > C variant genotyp
*Two-sided χ2 test for the distributions of genotype frequencies. †Adjusted for age andwere also associated larger tumor size. Our results are
consistent with some studies on other malignancies. For
example, Panguluri et al. reported that -765C allele was
associated with an increased risk of prostate cancer in
African Americans [24], and Koh et al. demonstrated
that an elevated risk of colon cancer in a Singapore
Chinese population [25]. There are also several studies
on the association between the COX-2 -765 G > C and
breast cancer risk; however, the results are inconclusive.
Recently, Yu et al. conducted a mete-analysis on this issue
and concluded that no significant association was observed
for the -765 G >C polymorphisms [15]. However, only two
studies enrolled in the mete-analysis were conducted in
Chinese population [18,19], which seems insufficient to
make a conclusive result in the population. Besides, in
consideration of the role of COX-2 in breast cancer, if
the polymorphism is associated with increased COX-25 G > C polymorphism and risk of breast cancer
Control (N = 799) P* OR (95% CI)†
%
90.4 0.049 1.00 (reference)
9.6 1.61 (1.00–2.61)
89.5 0.053 1.00 (reference)
10.5 1.60 (0.96–2.68)
es (GC/CC) were more pronounced in younger subjects rather than old subjects.
age at menarche.
Table 4 The associations between the COX-2 -765 G > C polymorphism and clinical characteristics of breast
cancer patients
Variables COX-2 -765 G > C genotypes P* OR (95% CI)†
GG (N, %) GC/CC (N, %)
Tumor size
Less than 2 cm 116 (92.1) 10 (7.9) 0.006 1.00 (reference)
More than 2 cm 278 (82.0) 61 (18.0) 3.01 (1.47–6.12)
LN involvement
Negative 206 (82.1) 45 (17.9) 0.084 1.00 (reference)
Positive 188 (87.9) 26 (12.1) 0.63 (0.38–1.07)
ER
Negative 140 (86.4) 22 (13.6) 0.459 1.00 (reference)
Positive 254 (83.8) 49 (16.2) 1.27 (0.62–2.61)
PR
Negative 179 (85.7) 30 (14.3) 0.620 1.00 (reference)
Positive 215 (84.0) 41 (16.0) 0.97 (0.49–1.93)
HER-2
Negative 262 (84.8) 47 (15.2) 0.961 1.00 (reference)
Positive 132 (84.6) 24 (15.4) 1.07 (0.61–1.86)
ER, estrogen receptor; PR, progestin receptor; LN, lymph node; HER-2, human epidermal growth factor receptor 2; CI, confidence interval; OR, odds ratio. The
frequency of the variant genotypes of COX-2 -765 G > C polymorphism was significant higher in patients with larger tumor size (>2 cm). *Two-sided χ2 test for
the distributions of genotype and allele frequencies. †Adjusted for tumor size, LN involvement, ER, PR and HER-2 status.
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ally plausible. However, there is still need to investigate
the functional effect of the COX-2 -765 G > C polymorph-
ism in breast cancer.
In the subgroup analysis, we found the increased risk
associated with the COX-2 -765 G >C polymorphism was
more prominent in individuals younger than 52 years of
age. As it is known, as age increases, individuals are more
susceptible to many types of cancer, thus the small effect
of the polymorphism may be overwhelmed. However, this
observation should be interpreted with caution since
we can not rule out the possibility that the number of
older women in the older section have been decreased
by deaths. We also observed that the COX-2 -765 GC/
CC genotypes was associated with larger tumor size. As
we mentioned above, over-expression of COX-2 correlated
with parameters of aggressive breast cancer, including
large tumor size, positive axillary lymph node metastases,
and HER2-positive tumor status. A better understanding
of the function of the polymorphism in breast cancer may
help to reveal the mechanism underlying the associations.
However, the results should be interpreted cautiously
since there is the possibility that the association may due
to a late stage at diagnosis. Nevertheless, if confirmed
by additional studies, this polymorphism may help to
accurately predict the clinical course of breast cancer.
As our study was hospital-based design, we could not
rule out the possible of selection bias of subjects that
may have been associated with a particular genotype.However, the genotype distributions of the COX-2 poly-
morphism in our study population were similar to distri-
butions reported in other studies [18], and also similar to
the distributions reported in the HapMap database for
Han Chinese in Beijing [5.2% vs. 6.7% for -765 G >C and
20.3 vs. 19.5 for 8473 C > T]. Besides, the genotype distri-
butions of the COX-2 polymorphisms in our study popula-
tion all conformed to HWE. Therefore, the selection bias
in terms of genotype distribution would not be substantial.
In conclusion, our case-control study indicates that
the COX-2 -765 G > C polymorphism has a significant
influence on the occurrence and progression of breast can-
cer in the Chinese population. Further functional studies
are still required to investigate the role of -765 G >C vari-
ation in regulating the gene expression in breast cancer.
Since our sample size is moderate and the statistical power
of the study is limited, therefore, large population-based
prospective studies are warranted to further elucidate the
impact of the COX-2 polymorphisms on breast cancer.Competing interest
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